Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Robert, Benamouzig, Bernard, Uzzan, Jacques, Deyra, Antoine, Martin, Bernard, Girard, Julian, Little, Stanislas, Chaussade, E, Zafrani
Publikováno v:
Gut
Gut, 2012, 61 (2), pp.255-261. ⟨10.1136/gutjnl-2011-300113⟩
Gut, 2012, 61 (2), pp.255-261. ⟨10.1136/gutjnl-2011-300113⟩
International audience; Background Aspirin inhibits colorectal carcinogenesis. In a randomised double-blind placebo-controlled trial, daily soluble aspirin significantly reduced recurrence of colorectal adenomas at 1-year follow-up. In this study the
Autor:
ZP Tsiamoulos, Alister Hart, Noriko Suzuki, Paul Bassett, Siwan Thomas-Gibson, Brian P. Saunders, T Elliott
Publikováno v:
Gut. 65:A198.2-A199
Introduction Delayed bleeding is the most common severe adverse event after p-Endoscopic Mucosal Resection (p-EMR) but factors that may predict delayed bleeding are not well-defined. Methods Data were analysed from a prospective single centre observa
Autor:
Andrew T. Chan
Publikováno v:
Gut. 59(5)
Four randomised, placebo-controlled studies have each shown that daily aspirin use reduces the occurrence of colorectal adenomatous polyps among individuals with a history of prior colorectal adenomas or cancer.1–4 In one of these trials, conducted
Publikováno v:
Gut. 62:A280.2-A281
Introduction Systematic investigation of patients with iron deficiency anaemia has been proven to yield a 12% diagnosis for colorectal cancer and 5% for coeliac disease 1 . Following publication of BSG guidelines, a nurse led protocol driven pathway
Autor:
Andrew F. Muller, L Pee
Publikováno v:
Gut. 59:A63.2-A64
Introduction The Bowel Cancer Screening Programme (BCSP) was introduced in England in 2006, with the expectation that screening would be available throughout England for the 60–69 years of age cohort by the end of 2009. Our own Trust began screenin